Explore the Agenda

7:45 am Chair’s Opening Remarks

Pharma Business Development Insights: Strategic Priorities & Deal Trends for Future Collaborations & Investment to Drive Disease Modification

8:00 am Pharma Icebreaker Discussion: From Fear of Better to Fear of Missing Out, Pharma’s Strategic Priorities Across Neuroscience

Director, Search & Evaluation, Rare & Neurological Disorders, Sanofi
Global Head, Neuroscience Search & Evaluation, Corporate Strategy, AbbVie
Corporate Development, Search & Evaluation Neuroscience, Biogen
Senior Director, Neuroscience, Eli Lilly
Associate Director, Business Development Search & Evaluation, Otsuka
Commercial Development Lead, Pfizer
Head Search & Evaluation, Neuroscience, Takeda
Head of Search & Evaluation Neuroscience, Novartis
  • Comparing sentiment towards neuroscience deal-making, including: which stage of development is most appealing, which modalities are of interest, and what are the key elements of differentiation?
  • Discussing data expectations to open a discussion. Guidance on data package and biomarker preferences seen as most credible or promising to generate interest for a deal decision
  • Providing the best advice on what is expected when approaching any partner, understanding how to differentiate decks in crowded and sharing insights into types of interactions around early-stage and pre-IND

8:45 am Short Comfort Break to Arrange Organized Networking Session

Networking Session: For Early Introductions & Breaking the Ice with Pharma

9:00 am Pharma Matchmaking Tables: Introductions to Pharma

External Innovation, Biogen
Neuroscience Search & Evaluation Lead, Takeda
Global Head, Neuroscience Search & Evaluation, Corporate Strategy, AbbVie
Corporate Development, Search & Evaluation Neuroscience, Biogen
Senior Director, Neuroscience, Eli Lilly
Associate Director, Business Development Search & Evaluation, Otsuka
Commercial Development Lead, Pfizer
Director, Search & Evaluation, Rare & Neurological Disorders, Sanofi
Head Search & Evaluation, Neuroscience, Takeda
Head of Search & Evaluation Neuroscience, Novartis

What is this session?

  • With a high concentration of relevant companies in one place, the pharma icebreaker tables offer a guaranteed opportunity for face-to-face interactions. Whether you’re connected on the One-on-One Partnering™ portal or not, this is a protected opportunity to introduce yourself and your organization

How is this organized?

  • Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selections to meet with companies they haven’t scheduled meetings with yet and are working in areas of strategic interest
  • With these selections, we will build a schedule of company rotations through each pharma’s table, across 90 minutes

10:45 am Morning Break & Networking Opportunity

11:00 am One-on-One PartneringTM Portal Opens for Private Meetings

The industry’s favorite partnering portal, search the full attendee list, message and schedule meetings in calendars ahead of the conference, and automatically book private meeting spaces in the room adjacent to the talks.

Novel Modalities: Where will There be Efficacy?

11:40 am How Advanced are New Modalities? Where are the Fields Opening Up?

Co-Founder & Chief Scientific Officer, Psilera
Chief Scientific Officer & Co-Founder, Kinoxis Therapeutics
Chief Executive Officer, Coya Therapeutics
Senior Vice President, Neuroscience, Argo Biopharma
Chief Business Officer, Splice Bio
  • Summarizing the field’s progress across disease areas, including the state of play of different modalities. How do you innovate beyond existing MoAs?
  • Considerations for the right modality: working with more established technologies versus promising new pharmacokinetics

12:00 pm One-on-One PartneringTM Portal Opens for Private Meetings

12:15 pm Lunch Break & Networking Opportunity

1:30 pm Showcase Your Science: Pipeline Innovation Partner Presentations

1st Presentation Session

Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience.

What is this session?

At the intersection of innovative research and business conversations, this forum facilitates the pitching of biotech pipelines and platforms to pharma and investors.

How does this session work?

As you register, secure one of the 15-minute presentation slots available in this presentation session. There will be no conflicting content happening to ensure a full and engaged audience listening to your presentation. We will add your talk to this brochure and on our website to showcase your differentiation in the best light, and host your company description and logo on the website as a company at the forefront of innovation.

Who can present?

Those developing in-house pipeline or platform technology, without any additional service provider capabilities, such as contract research or manufacturing.

2:30 pm Afternoon Break & Formal Networking Opportunity

2:30 pm One-on-One PartneringTM Portal Open

3:15 pm Showcase Your Science: Pipeline Innovation Partner Presentations

2nd Presentation Session

Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience.

What is this session?

To host as many innovative companies as possible on day one, this second session opens more presenting opportunities in front of the attending audience.

How does this session work?

Add a presentation slot to your registration through the website or by getting in touch, so you can generate interest in your assets ahead of the drinks reception. Once secured, submit your talk title and brief synopsis to us, as well as your dedicated speaker, and we will update this brochure to include you.

Who can present?

We are excited to host innovative science across Neurodegeneration, Neuropsychiatry and Neurooncology. Whether you are working on biologics, small molecules, gene or other advanced therapies, your senior scientific team would be a valued addition to this program.

Structuring Partnerships: From Proof of Concept to Creative Deal Structures

5:30 pm Effectively & Efficiently Structuring Deals as Small Neuroscience Companies

Chief Executive Officer, JEO Biotech Advisors
Head of BD&L Transactions Neuroscience, Novartis
Vice President, Business Development, CAMP4 Therapeutics
  • Discussing the panel’s experience executing and performing due diligence across neuroscience deals – what are the learnings from having partnerships with pharma?
  • Discussing how to get proof of concept earlier to secure additional investment or partnership
  • Outlining opportunities for creative deal structures, and when and where they would be appropriate

6:00 pm End of Conference Day One

6:00 pm Afternoon Drinks Reception & Networking

“People work with people”. Enjoy an informal networking drinks reception with all attending colleagues to catch up, candidly network, initiate and nurture business relationships built before or during the conference so far.

6:00 pm One-on-One PartneringTM Meeting Schedule Re-Opens

Available from 6.00 to 7.00 make the most of catching contacts away from the office and capitalize on meeting space adjacent to the networking drinks reception.